OKYO Pharma (NASDAQ: $OKYO), a clinical stage biopharmaceutical company, announced a major stability milestone for its drug candidate urcosimod on Monday, March 31, 2025. Details […]
Category: Biotech
Hoth Therapeutics (NASDAQ: HOTH) Unveils Plan To Submit HT-001 Expanded Access Application Amid Double Digit Growth in The Past Week: What To Know About Hoth
Hoth Therapeutics (NASDAQ: $HOTH), a clinical-stage biopharmaceutical working to develop innovative therapies, announced on Monday, March 10, 2025, that it planned to submit an Expanded […]
TG Therapeutics (NASDAQ: TGTX) Releases Q4 Fiscal 2024 Results Following Release Of Promising Data On New MS Drug: Is Now The Time To Invest In TGTX?
TG Therapeutics (NASDAQ: $TGTX), a commercial-stage biopharmaceutical company, released its Q4 fiscal 2024 results on Monday, March 3, 2025, before markets opened. Here is a […]
Aditxt (NASDAQ: ADTX) Subsidiary Pearsanta Prepares For IPO To Drive Launch Of Early Cancer Detection And Diagnosis Test in $31B Market
Aditxt (NASDAQ: $ADTX) announced on Friday, February 21, 2025, that its Subsidiary, Pearsanta, had engaged the services of a lead underwriter as it prepares for […]
Tiziana Life Sciences (NASDAQ: TLSA) Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program Amid Strong Momentum: Is TLSA Poised For A Major Breakout?
Tiziana Life Sciences (NASDAQ: $TLSA) is a biotech firm, which is working on comprehensive research efforts to advance novel treatments, and improve patient outcome with […]
Moderna (NASDAQ: MRNA) Sinks Then Rebounds After Bigger Than Expected Q4 Loss: Is Moderna Still A Great Investment in 2025?
Moderna (NASDAQ: $MRNA) posted its fourth-quarter results on Friday, February 14, 2025, beating revenue estimates. However, losses came in higher than expected, causing the stock […]